PNNL Proteome Characterization Center
PNNL 蛋白质组表征中心
基本信息
- 批准号:9210313
- 负责人:
- 金额:$ 112.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-21 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAffinityAmino Acid SequenceAreaBioinformaticsBiological AssayCancer BiologyCancer DiagnosticsCarcinomaCell LineCenter for Translational Science ActivitiesChromosomal RearrangementClassificationClinicalCollectionColorectal CancerComb animal structureDataData AnalysesDefectDevelopmentDiseaseEarly DiagnosisGasesGenomeGenomicsGoalsHereditary DiseaseHumanInformaticsLabelLaboratoriesLiquid ChromatographyMalignant NeoplasmsMalignant neoplasm of ovaryMeasurementMetalsMethodologyMethodsMutationOvarianPacific NorthwestPathway AnalysisPatientsPeptidesPerformancePhasePost-Translational Modification AlterationPost-Translational Protein ProcessingPre-Clinical ModelPreventionProcessProteinsProteomeProteomicsPublishingResearchResolutionSample SizeSamplingSerousSignal PathwaySignal TransductionSpecimenTechnologyThe Cancer Genome AtlasTherapeuticWorkXenograft procedurearmassay developmentbasecancer typedata integrationgenomic variationhuman tissueimprovedinformatics infrastructureinstrumentationmalignant breast neoplasmmembermultiple reaction monitoringnew technologynoveloutcome forecastovarian neoplasmpancreatic secretory trypsin inhibitor Iphosphoproteomicspre-clinicalprogramsprospectiveproteogenomicsquality assurancestoichiometrysuccesstandem mass spectrometrytechnology developmenttooltreatment strategytumor
项目摘要
PROJECT SUMMARY
The overall objective of the PNNL Proteome Characterization Center (PCC) is to integrate genomic information
with proteomic technologies to comprehensively characterize the proteome and post-translational modifications
(PTMs) as well as the functional interaction of proteins in signaling networks in cancers. As one of the PCCs in
the current Clinical Proteomic Tumor Analysis Consortium (CPTAC) program, PNNL successfully applied
advanced proteomics capabilities and expertise to the comprehensive proteogenomic and phosphoproteomic
characterization of ovarian high-grade serous carcinomas from The Cancer Genome Atlas, and has developed
novel mass spectrometric approaches to facilitate the analysis of intact proteins, low stoichiometry PTMs, and
extremely small samples. The planned PNNL PCC will build on these achievements and contribute to the
success of the CPTAC network by characterizing multiple new tumor types assigned by CPTAC, using both
the proven standardized, multiplexed discovery and targeted confirmatory workflows as well as introducing
novel technologies and platforms, as appropriate, to improve proteomic measurements. Both human
biospecimens and preclinical models provided by NCI will be analyzed.
The Discovery Research Arm will comprehensively characterize the proteome and multiple PTM-omes in
human biospecimens and preclinical samples of 2-3 cancers with the validated advanced proteomics
platforms, integrated workflows and informatics tools, using highly multiplexed isobaric labeling and state-of-
the-art liquid chromatography-tandem mass spectrometry instrumentation at a throughput of up to 300 samples
per year. The Confirmatory Research Arm will verify the impact of genomic variation on the changes in
proteome and PTM-omes with validated targeted proteomics platforms (e.g., multiple reaction monitoring),
peptide standards and quality assurance. Up to 100 highly specific, multiplexed targeted proteomics assays for
both proteins and PTMs will be developed each year for the confirmatory studies using up to 150 samples per
year. We will also refine and validate several developmental strategies and platforms at the PNNL PCC
leveraging our on-going technology development in areas such as ultrafast gas phase separations and small-
sized sample analysis platforms and methodologies to further improve the throughput and sensitivity in both
the discovery and confirmatory studies.
The PNNL PCC will work closely with the other PCCs, Proteogenomic Data Analysis Centers and
Proteogenomic Translational Research Centers in the CPTAC network on data integration and bioinformatics
analysis, as well as translational applications.
项目摘要
PNNL蛋白质组表征中心(PCC)的总体目标是整合基因组信息
利用蛋白质组学技术全面表征蛋白质组和翻译后修饰
(PTM)以及癌症信号网络中蛋白质的功能相互作用。作为一个PCCs,
目前的临床蛋白质组肿瘤分析联盟(CPTAC)计划,PNNL成功地应用于
先进的蛋白质组学能力和专业知识,以全面的蛋白质组学和磷酸化蛋白质组学
卵巢高级别浆液性癌的特征来自癌症基因组图谱,
新的质谱方法,以促进分析完整的蛋白质,低化学计量PTM,
非常小的样本。计划中的民族解放国家警察委员会将在这些成就的基础上再接再厉,
通过表征CPTAC分配的多种新肿瘤类型,
经过验证的标准化、多重发现和有针对性的确证工作流程,以及引入
新的技术和平台,以改善蛋白质组学测量。人力
将分析NCI提供的生物标本和临床前模型。
发现研究部门将全面表征蛋白质组和多个PTM-组,
使用经验证的先进蛋白质组学技术获得2-3种癌症的人体生物样本和临床前样本
平台,集成的工作流程和信息学工具,使用高度复用的同量异位素标记和状态,
最先进的液相色谱-串联质谱仪器,最多可处理300个样品
每一年。验证性研究组将验证基因组变异对
蛋白质组和PTM-组与经验证的靶向蛋白质组学平台(例如,多反应监测),
肽标准和质量保证。多达100种高特异性、多重靶向蛋白质组学检测,
每年都将开发蛋白质和PTM,用于使用多达150个样本的确证性研究,
年我们还将在PNNL PCC完善和验证几个发展战略和平台
利用我们在超快气相分离和小体积等领域的持续技术开发,
规模的样品分析平台和方法,以进一步提高在这两个通量和灵敏度
发现和验证性研究。
PNNL PCC将与其他PCC,蛋白基因组数据分析中心和
CPTAC数据整合和生物信息学网络中的蛋白质基因组转化研究中心
分析,以及翻译应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tao Liu其他文献
Tao Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tao Liu', 18)}}的其他基金
Center for Advanced Multi-Omic Characterization of Cancer
癌症高级多组学表征中心
- 批准号:
10439370 - 财政年份:2022
- 资助金额:
$ 112.38万 - 项目类别:
Center for Advanced Multi-Omic Characterization of Cancer
癌症高级多组学表征中心
- 批准号:
10631927 - 财政年份:2022
- 资助金额:
$ 112.38万 - 项目类别:
Center for Advanced Multi-Omic Characterization of Cancer
癌症高级多组学表征中心
- 批准号:
10755578 - 财政年份:2022
- 资助金额:
$ 112.38万 - 项目类别:
Targeted therapy against TERT oncogene-rearranged neuroblastoma
TERT癌基因重排神经母细胞瘤的靶向治疗
- 批准号:
10452641 - 财政年份:2021
- 资助金额:
$ 112.38万 - 项目类别:
Targeted therapy against TERT oncogene-rearranged neuroblastoma
TERT癌基因重排神经母细胞瘤的靶向治疗
- 批准号:
10287498 - 财政年份:2021
- 资助金额:
$ 112.38万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 112.38万 - 项目类别:
Continuing Grant